New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
14:55 EDTALXNAlexion informed Health Ministers will not follow AGNSS Soliris recommendation
Alexion Pharma UK, a subsidiary of Alexion Pharmaceuticals, announced it has been informed by the National Specialised Commissioning Team that the Ministers of Health have decided to not follow a positive recommendation by the Advisory Group for National Specialised Services, or AGNSS, when assessing Soliris as a treatment for patients with atypical haemolytic uraemic syndrome. The Ministers of Health have overruled this expert committee recommendation and instead referred consideration of Soliris for the treatment of patients with aHUS to the National Institute for Health and Clinical Excellence. Alexion said it is committed to working with the Health Ministers to make Soliris available to children and adults as quickly as possible, and calls upon the Ministers to accept the recommendation of the significant number of experts and lay people called upon to review Soliris without delay, and to reverse his decision and accept the recommendation of AGNSS in the best interests of aHUS patients in England. Alexion said, "It is important to underscore that the UK Government developed a specific process and authorised a committee, AGNSS, to evaluate treatments addressing patients with very rare disorders, and that AGNSS concluded that 'eculizumab should be routinely nationally commissioned for patients with aHUS.'"
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
06:38 EDTALXNAlexion granted European orphan drug designition to Soliris for MG treatment
Subscribe for More Information
July 25, 2014
07:44 EDTALXNAlexion valuation looking increasingly compelling, says Stifel
Subscribe for More Information
July 24, 2014
11:53 EDTALXNAlexion price target raised to $214 from $196 at Piper Jaffray
Subscribe for More Information
06:43 EDTALXNAlexion raises 2014 adjusted EPS view to $4.95-$5.05 from $4.75-$4.85
Subscribe for More Information
06:41 EDTALXNAlexion reports Q2 adjusted EPS $1.12, consensus $1.07
Subscribe for More Information
06:17 EDTALXNAlexion's hypophosphatasia candidate MAA accepted by European Medicines Agency
Subscribe for More Information
July 22, 2014
11:48 EDTALXNStocks with call strike movement; EXPE ALXN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use